GOP Congressman Chris Collins Indicted On Insider Trading Charges

Rep. Chris Collins (R-N.Y.) leaves the House Republican Conference meeting in the Capitol on June 20. (Bill Clark/CQ Roll Call)

Rep. Chris Collins (R-N.Y.) was indicted Wednesday on federal insider trading charges. Prosecutors alleged that he used information he received while on the board of an Australian biotechnology firm, Innate Immunotherapeutics, to tip off his son and others to sell the company’s stock before a damaging report on the company’s lack of success with a drug to treat multiple sclerosis.

The Associated Press has a story about the indictment and the complaint filed by the Securities and Exchange Commission.

Here’s a look at Kaiser Health News’ earlier coverage of Collins’ relationship with the company:

Congressman’s Ties To Foreign Biotech Draw Criticism

Report: Congressional Ethics Office Probing Rep. Chris Collins’ Aussie Investment

Rep. Chris Collins’ Australian Stock Bet Looks Bleaker

Trump’s HHS Nominee Got A Sweetheart Deal From A Foreign Biotech Firm

Related Topics

Health Industry Pharmaceuticals Public Health